thyssenkrupp orinoco manual
LINK 1 ENTER SITE >>> Download PDF
LINK 2 ENTER SITE >>> Download PDF
File Name:thyssenkrupp orinoco manual.pdf
Size: 3104 KB
Type: PDF, ePub, eBook
Category: Book
Uploaded: 1 May 2019, 18:46 PM
Rating: 4.6/5 from 649 votes.
Status: AVAILABLE
Last checked: 18 Minutes ago!
In order to read or download thyssenkrupp orinoco manual ebook, you need to create a FREE account.
eBook includes PDF, ePub and Kindle version
✔ Register a free 1 month Trial Account.
✔ Download as many books as you like (Personal use)
✔ Cancel the membership at any time if not satisfied.
✔ Join Over 80000 Happy Readers
thyssenkrupp orinoco manualFor this online version we have omitted the extensive first part dealing with deep sea and scuba diving. We have included only the second part on submarine medicine. This was done as an economy of effort as there are numerous other dive medicine references available, but little on submarine medicine. It provides a unique view into the conditions aboard US Diesel submarines.Different browsers and fonts will causeHowever, this text was captured by optical character recognition and then encoded for the Web which has added new errors we wish to correct.Much has been accomplished inFor the medical officer interested in the solutionIncreasing cruising range and prolonged submergence of modern submarines, penetration of greater depths byForces.U. S. Naval Submarine Base, New London, Conn.; and to the Experimental. Diving Unit and the U. S. Naval School, Deep Sea Divers, Naval Gun Factory. Washington, D. C.This arrangement is designed for theThe third and last number refers to a furtherFor example, DM-825 refers to Bureau of Ships. Diving Manual, paragraph 825. Likewise, MMD-15-30 refers to chapter 15,Other book references are similarly cited. It is difficult to know when a given review might become out of date, but tools are available to assist in identifying when a review might need updating. They are useful in rapidly evolving fields where research is published frequently. New technologies and better processes for data storage and reuse are being developed to facilitate the rapid identification and synthesis of new evidence. They are usually undertaken by a collaborative group including authors of the studies to be included, and they usually collect and analyse individual participant data. They should not be used for the main analyses, or to draw main conclusions. Sequential methods may, however, be used in the context of a prospectively planned series of randomized trials. Chapter 22: Prospective approaches to accumulating evidence.http://dorapeyzaj.com/userfiles/devilbiss-at10-impact-wrench-manual.xml
- Tags:
- thyssenkrupp orinoco manual, thyssenkrupp orinoco manual transmission, thyssenkrupp orinoco manual parts, thyssenkrupp orinoco manual pdf, thyssenkrupp orinoco manual user.
In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020).Thousands of systematic reviews are now published in the Cochrane Database of Systematic Reviews, presenting critical summaries of the evidence. However, maintaining the currency of these reviews through periodic updates, consistent with Chalmers’ vision, has been a challenge. A prospective meta-analysis (PMA) begins with the idea that future studies will be integrated within a systematic review and works backwards to plan a programme of trials with the explicit purpose of their future integration. The retrospective nature of most systematic reviews poses an inevitable challenge, in that the selection of what types of evidence to include may be influenced by authors’ knowledge of the context and findings of the available studies. This might introduce bias into any aspect of the review’s eligibility criteria including the selection of a target population, the nature of the intervention(s), choice of comparator and the outcomes to be assessed. The best way to overcome this problem is to identify evidence entirely prospectively, that is before the results of the studies are known. Section 22.3 describes such prospectively planned meta-analyses. Cochrane actively discourages use of the notion of statistical significance in favour of reporting estimates and confidence intervals, so such concerns should not arise. Nevertheless, sequential approaches are an established method in randomized trials, and may play a role in a prospectively planned series of trials in a prospective meta-analysis. For many years, a policy was in place of updating each Cochrane Review at least every two years.http://cnzhongkui.com/fckeditor/editor/filemanager/connectors/php/uploads/file/2020/09/191847024445.xml This policy was not closely followed due to a range of issues including: a lack of resources; the need to balance starting new reviews with maintaining older ones; the rapidly growing volume of research in some areas of health care and the paucity of new evidence in others; and challenges in knowing at any given point in time whether a systematic review was out of date and therefore possibly giving misleading, and potentially harmful, advice. For example, one study suggested that while the conclusions of most reviews might be valid for five or more years, the findings of 23 might be out of date within two years, and 7 were outdated at the time of their publication (Shojania et al 2007). Systematic reviews in rapidly evolving fields are particularly at risk of becoming out of date, leading to the development of a range of methods for identifying when a systematic review might need to be updated. Garner and colleagues have refined this tool and described a staged process that starts by assessing the extent to which the review is up to date (including relevance of the question, impact of the review and implementation of appropriate and up-to-date methods), then examines whether relevant new evidence or new systematic review methodology are available, and then assesses the potential impact of updating the review in terms of whether the findings are likely to change (Garner et al 2016). For a detailed discussion of updating Cochrane Reviews, see online Chapter IV. See Section 22.2.4 for further information on technological approaches to ameliorate this. Sample size calculations can incorporate the result of a current meta-analysis, thus providing information about how additional studies of a particular sample size could have an impact on the results of an updated meta-analysis (Sutton et al 2007, Roloff et al 2013).https://congviendisan.vn/vi/boss-loop-station-manual-rc-3 These methods demonstrate in many cases that new evidence may have very little impact on a random-effects meta-analysis if there is heterogeneity across studies, and they require assumptions that the future studies will be similar to the existing studies. Their practical use in deciding whether to update a systematic review may therefore be limited. Their prediction equation involved two of these signals: the ratio of statistical information (inverse variance) in the new versus the original studies, and the number of new studies. Further work is required to develop ways to operationalize this approach efficiently, as it requires detailed knowledge of the new evidence; once this is in place, much of the effort to perform the update has already been expended. Ongoing developments in technology, which we overview in Section 22.2.4. An important issue when setting up an LSR is that the search methods and anticipated frequency of review updates are made explicit in the review protocol. This transparency is helpful for end-users, giving them the opportunity to plan downstream decisions around the expected dates of new versions, and reducing the need for others to plan or undertake review updates. Practical guidance on initiating and maintaining LSRs has been developed by the Living Evidence Network. Fortunately, new developments in information and computer science offer some potential for reductions in manual effort through automation. (For an overview of a range of these technologies see Chapter 4, Section 4.6.6.2.) As these datasets continue to grow to contain all relevant records in their respective areas, they may also reduce the need for author teams to search as many different sources as they currently need to. Automation tools that are built on large numbers of records for more generic use are also available, such as Cochrane’s RCT Classifier, which can be used to filter studies that are unlikely to be randomized trials from a set of records (Thomas et al 2017).https://cristianpack.com/images/99-mazda-millenia-owners-manual.pdf Cochrane has also developed Cochrane Crowd, which crowdsources decisions classifying studies as randomized trials, (see Chapter 4, Section 4.6.6.2 ). These include risk-of-bias assessment, the extraction of structured data from tables in PDF files, information extraction from reports (such as identifying the number of participants in a study and characteristics of the intervention) and even the writing of review results. These technologies are less well-advanced than those used for study identification. However, Cochrane is also setting up systems that aim to change the study selection process quite substantially, as depicted in Figure 22.2.a. These developments begin with the prospective identification of relevant evidence, outside of the context of any given review, including bibliographic and trial registry records, through centralized routine searches of appropriate sources. First, the type of study is determined and, if it is likely to be a randomized trial, then the record proceeds to be classified in terms of its review topic and its PICO elements using terms from the Cochrane Linked Data ontology. Finally, relevant data are extracted from the full text report. The viability of such a system depends upon its accuracy, which is contingent on human decisions being consistent and correct. For this reason, the early focus on randomized trials is appropriate, as a clear and widely understood definition exists for this type of study. Overall, the accuracy of Cochrane Crowd for identification of randomized trials exceeds 99; and the machine learning system is similarly calibrated to achieve over 99 recall (Wallace et al 2017, Marshall et al 2018). For example, in the past the same decisions about the same studies have been made multiple times across different reviews because previously there was no way of sharing these decisions between reviews. Duplication in manual effort is being reduced substantially by ensuring that decisions made about a given record (e.g. whether or not it describes a randomized trial) are only made once. These decisions are then reflected in the inclusion of studies in the Cochrane Register of Studies, which can then be searched more efficiently for future reviews. The system benefits further from its scale by learning that if a record is relevant for one review, it is unlikely to be relevant for reviews with quite different eligibility criteria. Ultimately, the aim is for randomized trials to be identified for reviews through a single search of their PICO classifications in the central database, with new studies for existing reviews being identified automatically. Systematic reviews are by nature, however, retrospective because the trials included are usually identified after the trials have been completed and the results reported. A prospective meta-analysis (PMA) is a systematic review and meta-analysis of studies that are identified, evaluated and determined to be eligible for the meta-analysis before the relevant results of any of those studies become known. Most experience of PMA comes from their application to randomized trials. In this section we focus on PMAs of trials, although most of the same considerations will also apply to systematic reviews of other types of studies. They have tended to involve collecting individual participant data (IPD), such that they have many features in common with retrospective IPD meta-analyses (see also Chapter 26 ). For example, the investigators may agree to use the same instrument to measure a particular outcome, and to measure the outcome at the same time-points in each trial. In a Cochrane Review of interventions for preventing obesity in children, for example, the diversity and unreliability of some of the outcome measures made it difficult to combine data across trials (Summerbell et al 2005). A PMA of this question proposed a set of shared standards so that some of the issues raised by lack of standardization could be addressed (Steinbeck et al 2006). There are areas such as infectious diseases, however, where the opportunity to use PMA has largely been missed (Ioannidis and Lau 1999). However, it is possible to harmonize data for inclusion in meta-analysis. However, whereas traditional multicentre trials implement a single protocol across all sites to reduce variability in trial conduct among centres, PMAs allow investigators greater flexibility in how their trial is conducted. Sites can follow a local protocol appropriate to local circumstances, with the local protocol being aligned with elements of a PMA protocol that are common to all included trials. They may also be useful when two or more trials addressing the same question are started with the investigators ignorant of the existence of the other trial(s): once these similar trials are identified, investigators can plan prospectively to combine their results in a meta-analysis. For example, FICSIT (Frailty and Injuries: Cooperative Studies of Intervention Techniques) was a pre-planned meta-analysis of eight trials of exercise-based interventions in a frail elderly population (Schechtman and Ory 2001). The eight FICSIT sites defined their own interventions using site-specific endpoints and evaluations and differing entry criteria (except that all participants were elderly). Because the collaboration must be formed before the results of any trial are known, an important focus of a PMA’s collaborative efforts is often on reaching agreement on trial population, design and data collection methods for each of the participating trials. Ideally, the collaborative group will agree on a core common protocol and data items (including operational definitions) that will be collected across all trials. While individual trials can include local protocol amendments or additional data items, the investigators should ensure that these will not compromise the core common protocol elements. For an example protocol, see the NeOProM Collaboration protocol (Askie et al 2011). Developing a protocol for a PMA is conceptually similar to the process for a systematic review with a traditional meta-analysis component (Moher et al 2015). However, some considerations are unique to a PMA, as follows. In addition, it should specify which outcomes will be measured by all trials in the PMA, and when and how these should be measured. Additionally, details of subgroup analysis variables should be specified. The protocol should describe in detail the efforts made to identify ongoing, or planned trials, or to identify trialists with a common interest in developing a PMA, including how potential collaborators have been (or will be) located and approached to participate. The protocol should state whether a signed agreement to collaborate has been obtained from the appropriate representative of each trial (e.g. the sponsor or principal investigator). The protocol should include a statement that, at the time of inclusion in the PMA, no trial results related to the PMA research question were known to anyone outside each trial’s own data monitoring committee. If eligible trials are identified but not included in the PMA because their results related to the PMA research question are already known, the PMA protocol should outline how these data will be dealt with. For example, sensitivity analyses including data from these trials might be planned. The protocol should describe actions to be taken if subsequent trials are located while the PMA is in progress. Details of overall sample size and power calculations, interim analyses (if applicable) and subgroup analyses should be provided. For a prospectively planned series of trials, a sequential approach to the meta-analysis may be reasonable (see Section 22.4 ). Would the PMA secretariat, for example, accept appropriate summary data. The protocol should specify whether there is an intention to update the PMA data at regular intervals via ongoing cycles of data collection (e.g. five yearly). A detailed statistical analysis plan should be agreed and made public before the receipt or analysis of any data to be included in the PMA. In addition to contributing to the PMA, it is likely that investigators will prefer trial-specific publications to appear before the combined PMA results are published. It is recommended that PMA publication(s) clearly indicate the sources of the included data and refer to prior publications of the individual included trials. As trialists prospectively decide which data they will collect and in what format, the need to re-define and re-code supplied data should be less problematic than is often the case with a retrospective IPD meta-analysis. PMA offers a unique opportunity to perform these interim analyses using data contributed by all trials. Under the auspices of an over-arching data safety monitoring committee (DSMC) for the PMA, available data may be combined from all trials for an interim analysis, or assessed separately by each trial and the results then shared amongst the DSMCs of all the participating trials. Is it, for example, appropriate to continue randomization within individual trials if an overall net benefit of an intervention has been demonstrated in the combined analysis. When results are not known in the subgroups of clinical interest, or for less common endpoints, should the investigators continue to proceed with the PMA to obtain further information regarding overall net clinical benefit. If each trial has its own DSMC, then communication amongst committees would be beneficial in this situation, as recommended by Hillman and Louis (Hillman and Louis 2003). This would be helpful, for example, in deciding whether or not to close an individual trial early because of evidence of efficacy from the combined interim data. It could be argued that knowledge of emerging, concerning, combined safety data from all participating trials might actually reduce the chances of spurious early stopping of an individual trial.In any case, it might be appropriate to apply the concepts of sequential meta-analysis methodology, as discussed in Section 22.4, to derive stringent stopping rules for the PMA as individual trial results become available. The approach aims to take all eligible trials into account, including those that have been completed (and analysed) and those that are yet to complete or report (Tierney et al 2017). FAME can be used to anticipate the earliest opportunity for a reliable aggregate data meta-analysis, which may be well in advance of all relevant results becoming available. The key steps of FAME are as follows. Conference proceedings, study registers and investigator networks are therefore important sources of information. Although unpublished and ongoing studies should be examined for any systematic review, evidence suggests that it is not standard practice (Page et al 2016). In other words they would provide sufficient power to detect realistic effects of the intervention under investigation, on the basis of standard methods of sample size calculation. This serves to minimize the likelihood of reporting or other data availability biases. Such predictions and decisions for FAME should be outlined in the systematic review protocol. This is in addition to the direction and precision of the meta-analysis result and consistency of effects across trials, as is standard. In these reviews, collaboration with trial investigators provided access to pre-publication results, expediting the review process further and allowing publication in the same time frame as key trial results, increasing the visibility and potential impact of both. It also enabled access to additional outcome, subgroup and toxicity analyses, which allowed a more consistent and thorough analysis than is often possible with aggregate data. Such an approach requires a suitable non-disclosure agreement between the review authors and the trial authors. Combining multiple FAME reviews in a network meta-analysis (Vale et al 2018) offers an alternative to living network meta-analysis for the timely synthesis of competing treatments (Crequit et al 2016, Nikolakopoulou et al 2018). Such an incorrect conclusion is often called a type I error. If significance tests are repeated each time a meta-analysis is updated with new studies, then the probability that at least one of the repeated meta-analyses will produce a P value lower than 0.